Kalvista Pharmaceuticals Inc (KALV)

Jan 21, 2025

Japan grants orphan drug status to HAE treatment - Investing.com India

Jan 21, 2025

Jan 21, 2025

KalVista's Sebetralstat Scores Dual Regulatory Wins in Japan for HAE Treatment - StockTitan

Jan 21, 2025

Jan 21, 2025

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema - The Bakersfield Californian

Jan 21, 2025

Jan 21, 2025

Hennion & Walsh Asset Management Inc. Makes New Investment in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Jan 21, 2025

Jan 19, 2025

KalVista wins new Buy at BofA on potential of lead candidate - MSN

Jan 19, 2025

Jan 16, 2025

Barclays PLC Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Jan 16, 2025

Jan 08, 2025

KalVista Pharmaceuticals Awards Strategic Employee Stock Options Worth 111,000 Shares - StockTitan

Jan 08, 2025

Jan 08, 2025

TD Cowen Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation - MSN

Jan 08, 2025

Jan 08, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jan 08, 2025

Jan 08, 2025

TD Cowen backs Kalvista stock as peak sales potential for sebetralstat exceeds $750MM - Investing.com Canada

Jan 08, 2025

Jan 07, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at TD Cowen - MarketBeat

Jan 07, 2025

Jan 02, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Holdings Raised by Geode Capital Management LLC - Defense World

Jan 02, 2025

Jan 01, 2025

Barclays PLC Raises Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Jan 01, 2025

Dec 26, 2024

How the (KALV) price action is used to our Advantage - Stock Traders Daily

Dec 26, 2024

Dec 25, 2024

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by State Street Corp - MarketBeat

Dec 25, 2024

Dec 25, 2024

State Street Corp Buys 515,179 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Dec 25, 2024

Dec 23, 2024

KalVista Pharmaceuticals Inc (NASDAQ: KALV) Is The Number One Stock Currently Moving. - Stocks Register

Dec 23, 2024

Dec 20, 2024

KALV Stock Touches 52-Week Low at $8.20 Amid Market Challenges - Investing.com Canada

Dec 20, 2024

Dec 18, 2024

KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025 - Seeking Alpha

Dec 18, 2024

Dec 18, 2024

BofA Securities sets price target on Kalvista shares with Buy rating - Investing.com Australia

Dec 18, 2024

Dec 18, 2024

KalVista stock wins new Buy at BofA (KALV:NASDAQ) - Seeking Alpha

Dec 18, 2024

Dec 18, 2024

KalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at Bank of America - MarketBeat

Dec 18, 2024

Dec 18, 2024

Fmr LLC Increases Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Dec 18, 2024

Dec 17, 2024

KalVista appoints new COO amid operational growth By Investing.com - Investing.com Canada

Dec 17, 2024

Dec 16, 2024

KalVista Pharmaceuticals, Inc. Appoints Jeb Ledell as Chief Operating Officer - Marketscreener.com

Dec 16, 2024

Dec 16, 2024

KalVista appoints new COO amid operational growth - Investing.com

Dec 16, 2024

Dec 16, 2024

KalVista Pharmaceuticals Appoints New COO Amid Strategic Growth - TipRanks

Dec 16, 2024

Dec 16, 2024

KalVista Pharmaceuticals appoints Jeb Ledell as COO - Seeking Alpha

Dec 16, 2024

Dec 16, 2024

KalVista Appoints Jeb Ledell as Chief Operating Officer - The Bakersfield Californian

Dec 16, 2024

Dec 16, 2024

KalVista Pharmaceuticals Taps Former AVEO Oncology Executive as New COO in Strategic Leadership Move - StockTitan

Dec 16, 2024

Dec 13, 2024

KALV Stock Touches 52-Week Low at $8.74 Amid Market Challenges - Investing.com Canada

Dec 13, 2024

Dec 12, 2024

KALV Stock Touches 52-Week Low at $8.74 Amid Market Challenges By Investing.com - Investing.com South Africa

Dec 12, 2024

Dec 10, 2024

KalVista Pharmaceuticals (NASDAQ:KALV) Given “Overweight” Rating at Cantor Fitzgerald - Defense World

Dec 10, 2024

Dec 09, 2024

KalVista CEO Benjamin Palleiko sells shares worth $74,363 By Investing.com - Investing.com Canada

Dec 09, 2024

Dec 09, 2024

KalVista CEO Benjamin Palleiko sells shares worth $74,363 - Investing.com

Dec 09, 2024

Dec 09, 2024

What is HC Wainwright's Forecast for KALV FY2029 Earnings? - MarketBeat

Dec 09, 2024

Dec 09, 2024

What is HC Wainwright’s Forecast for KALV FY2029 Earnings? - Defense World

Dec 09, 2024

Dec 08, 2024

KALVKalVista Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Dec 08, 2024

Dec 07, 2024

KalVista Pharmaceuticals' (KALV) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Dec 07, 2024

Dec 06, 2024

KalVista shares hold buy rating on HAE drug outlook - Investing.com

Dec 06, 2024

Dec 06, 2024

KalVista shares hold buy rating on HAE drug outlook By Investing.com - Investing.com Nigeria

Dec 06, 2024

Dec 05, 2024

KalVista Pharmaceuticals Reports Progress in HAE Treatment - TipRanks

Dec 05, 2024

Dec 05, 2024

180,000 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Purchased by Readystate Asset Management LP - MarketBeat

Dec 05, 2024

Dec 05, 2024

KalVista Pharmaceuticals Inc. (KALV) reports earnings - Quartzy

Dec 05, 2024

Dec 05, 2024

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update - citybiz

Dec 05, 2024

Dec 04, 2024

Trading (KALV) With Integrated Risk Controls - Stock Traders Daily

Dec 04, 2024